Kornimate/medical-research-clean huggingface dataset:
efficacy testing of hibiscus sabdariffa extract and collagen products

Conditions: Skin Condition

Summary: to assess hibiscus sabdariffa extract and collagen products on skin condition improvement


Eligibility criteria:
inclusion criteria: * healthy adults aged above 20 years old exclusion criteria: * subject who is not willing to participate in this study. * patients with diseases of the skin, liver, kidney. * subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder. * female who is pregnant or nursing or planning to become pregnant during the course of the study. * received facial laser therapy, chemical peeling or uv overexposure (\> 3 hr/week) in the past 4 weeks. * constant drug use * students who are currently taking courses taught by the principal investigator of this trial.
vorinostat in combination with bortezomib, doxorubicin and dexamethasone (vbdd) in patients with refractory or relapsed multiple myeloma (mm)

Conditions: Multiple Myeloma in Relapse

Summary: primary objective of the study is the determination of the maximum tolerated dose (mtd) of vorinostat (v), given in combination with fixed doses of doxorubicin (d), bortezomib (b) and dexamethasone (d). secondary objectives are: assessment of safety and tolerability of vbdd; efficacy data of vbdd.

a first cohort of three patients will be treated at the starting dose level of vorinostat 100 mg/d, on day 1-4, 8-11, and 15-18 in combination with bdd. the dose level of vorinostat will be escalated in each new cohort: if no dose limiting toxicity (dlt) has been observed in the previous dose level in 3 patient, the second cohort of 3 new patients will be treated with vorinostat 200 mg/d and the third cohort will be given vorinostat with 300 mg/d. bortezomib will be administered intravenously (i.v.) 1.3mg/m2 d1, 8, 15. doxorubicin will be administered i.v. with a total dose of 18 mg/m2 per cycle (9 mg/m2, d1 and 8). dexamethasone will be administered per os (p.o.) with 40mg (first cycle) and 20mg (all other subsequent cycles) on d1, 8, 15, 22.

Eligibility criteria:
inclusion criteria: * patients with refractory or relapsed mm after at least first-line chemotherapy (ctx) or pbsct (autologous and allogeneic sct). all lines of relapse are eligible. * kps ≥60% * adequate bm function * adequate hepatic and renal function (ast and alt ≤2.5 times uln, bilirubin ≤1.5 times uln, egfr \>20 ml/min) exclusion criteria: * patient has had prior treatment with vorinostat or hdac inhibitors * patients with severe hepatic impairment or acute diffuse infiltrative pulmonary and pericardial disease * patient has preexisting nci ctc ≥grade 3 neuropathy * patient with known cns mm-involvement and/or mm-related/induced meningitis

Keywords: multiple myeloma relapsed refractory
the effects of virtual reality in intensive care patients

Conditions: Virtual Reality; Intensive Care Unit Acquired Weakness

Summary: weakness of respiratory muscles delays weaning from the ventilator, prolongs hospital stay and increases treatment costs. conventional treatments for respiratory muscles reverse these negative effects. i̇ntensive care services are a set of services that have a very important place in public health care due to the vital support and they provide to all critically ill patients. this care services are constantly improving with the use of technological innovations. with the development of technology, virtual reality application has begun to be used therapeutically in the field of physiotherapy. virtual reality is the combination of reality and imagination with fictions created using technology. today, developers can surprisingly create realistic worlds filled with artificial intelligence that behaves believably. studies have shown positive effects of virtual reality on acute respiratory frequency, pain and fatigue, and in light of this, it was predicted that it would be beneficial to apply to intensive care patients. this study will shed light on the rehabilitation of patients in intensive care and contribute to the literature.

in the study, it was aimed to benefit from the effects of virtual reality application in intensive care patients and have a positive effect on vital signs and respiratory parameters in the early period. this study will be randomly divided into two groups and it is planned to include 17 partipitants in each group. the first group will receive only conventional treatment, and the second group will receive virtual reality application in addition to conventional treatment. to evaluate the effectiveness of the application, vital signs, respiratory muscle strength, grip strength, blood gas analysis, shortness of breath and fatigue will be evaluated. additionally, richmond agitation sedation scale (rass), nonverbal pain scale, glaskow coma scale, physical function test in intensive care (pfit)-cpax (chelsea critical care physical assessment tool) scales will be used. all evaluations will be made before and after the application and a comparison will be made between the two groups.

Eligibility criteria:
inclusion criteria: * individuals receiving inpatient treatment in intensive care who volunteer to participate in the research or who are allowed by their first-degree relatives if they are unconscious, * being over 18 years of age * being eligible to receive physiotherapy and rehabilitation from an intensive care physician * are in clinically stable condition exclusion criteria: * patients with coagulation disorders (pt (prothrombin time); inr (international normalized ratio) value higher than 1.5 and platelet amount less than 50,000 m³) * patients with signs of increased intracranial pressure * skin wounds, ulcerations, allergic reactions * patients in contact isolation due to infection * in shock * having malignancy * having multiple organ failure * having visual impairment * patients who are unconscious

Keywords: virtual reality intensive care respiratory muscle strength respiratory function
local infiltration analgesia with ropivacaine in posterior vaginal wall prolapse:a randomized, double-blind study

Conditions: Vaginal Prolapse

Summary: the purpose of this study is to compare systematic local infiltration with ropivacaine or placebo in patients undergoing repair of posterior vaginal wall prolapse. the hypothesis is that lia technique is opioid-sparing and a better postoperative treatment.


Eligibility criteria:
inclusion criteria: * eligible for elective repair of posterior vaginal wall prolapse * able to speak and understand danish * able to give informed consent exclusion criteria: * alcohol or medical abuse * allergies to local anesthetics * age \< 18 yrs. * intolerance to opioids

Keywords: postoperative pain ponv
pain relief of newborn preterm infants during endotracheal suctioning

Conditions: Pain

Summary: evaluate the effectiveness of the use of a 24% sucrose solution for pain management of preterm infants during endotracheal suctioning.

many infants admitted to neonatal intensive care unit (nicu) undergo repeated invasive procedures. recent studies have shown that the oral sucrose administration to neonates is safe and effective for pain relief during heel stick and venipuncture.most data suggest the investigation of the effect of sucrose in other painful procedures such as in ventilated newborns.

Eligibility criteria:
inclusion criteria: * preterm infants * over 12 hours of life * intubated * clinically stable * without use of analgesics or sedatives exclusion criteria: * preterms with congenital malformations * preterms with genetic syndromes * preterms with apgar score at 5´\<7 * preterms with meningitis * preterms with diagnosed of necrotizing enterocolitis ouvir ler foneticamente

Keywords: pain sucrose newborn mechanical ventilation
observational study of patients with mucopolysaccharidosis (mps) vi who previously participated in asb-00-02

Conditions: MPS VI

Summary: there is limited information on the long-term effects of treating patients with mps vi with naglazyme® and limited data on the natural history of treated and untreated mps vi patients. the re-survey study asb-00-03 will assist in understanding the effects of long-term naglazyme treatment and the natural history of the mps vi patient population.


Eligibility criteria:
inclusion criteria: * willing and able to provide written, signed informed consent, or in the case of patients under the age of 16 years, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures. * previously participated in survey study asb-00-02, and met the criteria of a mps vi diagnosis. * willing to perform all study assessments and procedures as physically possible. exclusion criteria: * concurrent disease or condition that would interfere with study participation or safety. * any condition that, in the view of the investigator would place the patient at high risk of not completing the study. * concurrent enrollment and randomization into a clinical study of mps vi treatment. patients enrolled in the biomarin mps vi clinical surveillance program may be enrolled in the re-survey study asb-00-03.
tau imaging in professional fighters

Conditions: Alzheimer's Disease

Summary: subjects enrolled in the professional fighters brain health study (pfbhs) will receive flortaucipir to explore its use as a biomarker for brain injury related to repetitive head trauma and to examine the relationship between clinical presentation and tau deposition.


Eligibility criteria:
inclusion criteria: all subjects * currently enrolled in the pfbhs protocol and have participated in a minimum of 10 professional fights * can tolerate positron emission tomography (pet) scan procedures * have the ability to provide informed consent subjects with cognitive impairment * have subjective cognitive complaints or objective decline or impairment as determined by the investigator exclusion criteria: * have behavior dysfunction that is likely to interfere with imaging * are claustrophobic or otherwise unable to tolerate the imaging procedure * have current clinically significant cardiovascular disease or clinically significant abnormalities on screening electrocardiogram * a history of additional risk factors for torsades de pointes (tdp) or are taking drugs that are known to cause qt-prolongation * have a current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer * have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session * have current drug or alcohol dependence or alcohol dependence within the past 2 years
screening for nafld-related advanced fibrosis in high risk population in diabetology.

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: nonalcoholic fatty liver disease (nafld) is being recognized as one of the most prevalent causes of chronic liver disease worldwide. the current strategy proposed by the easl/easo/easd european guidelines for the screening of nonalcoholic fatty liver disease (nafld) in high-risk population such as type 2 diabetes and patients with obesity leads to an over-referral in hepatology clinics. the proposed study will investigate the optimal strategy for the screening of nafld-related advanced fibrosis in patients at high risk of fibrotic nafld, such as patients with t2dm or obesity by maximizing the positive predictive value (ppv) using non-invasive blood and elastography-based biomarkers in endocrinology/diabetology clinics in order to reduce the over-referral to hepatology clinics.


Eligibility criteria:
inclusion criteria: * patient aged between 40 and 80 years old, * patients with diagnosis of t2dm\* or obesity (defined according to world health organization as a bmi≥ 30 kg/m2) * patient with hepatic steatosis determined by conventional abdominal ultrasound as defined by the easl/easo/easd european guidelines. * patient who agrees to be included in the study and who signs the informed consent form, * patient affiliated to a healthcare insurance plan. exclusion criteria: * evidence of other causes of chronic liver disease: * history of ingestion of medications known to produce steatosis in the previous 6 months. * evidence of cirrhosis or previously known cirrhosis based on the results from previous liver biopsy or history of portal hypertension presented by ascites, hepatic encephalopathy or varices * presence of regular and/or excessive use of alcohol (defined as \>30g/day for males and \>15g/day for females) for a period longer than 2 years at any times in the last 10 years * the subject is a pregnant or nursing female * life expectancy less than 5 years * history of known hiv infection * history of type 1 diabete * bmi ≥ 40 kg/m2 * mentally unbalanced patients, under supervision or guardianship, * patient deprived of liberty, * patient who does not understand french/ is unable to give consent, * patient already included in a trial who may interfere with the study or in a period of exclusion following participation in a previous study.

Keywords: nafld type 2 diabete obesity advanced fibrosis cirrhosis
a study to investigate the analgesic efficacy of ibuprofen alone and ibuprofen plus hyoscine-n- butyl bromide in reducing pain of outpatient hysteroscopy

Conditions: Pain

Summary: for outpatient hysteroscopy (oh), it is recommended to take a standard dose of nsaids or more hyoscine-n butyl bromide (hbb) an hour prior to the procedure to minimize pain during the first postoperative hour. as there is currently no clear consensus in the literature regarding the best approach to pain management associated with office hysteroscopy procedures. this phase 4 study is being conducted to evaluate the effectiveness of oral ibuprofen alone and in combination with hbb to determine the most appropriate strategy for improving pain perception in outpatients.

this is a randomized, phase iv, double-blind, placebo-controlled clinical trial. the subjects will be randomly assigned into one of two treatment arms: * group a (ibuprofen ): will receive one tablet of ibuprofen 400 mg and two tablets of placebo (similar in size, structure and colour to hbb) * group b (ibuprofen plus hhb): will assume one tablet of ibuprofen 400 mg plus two tablets of hhb 10 mg. the purpose of this study is to evaluate the effectiveness of oral ibuprofen alone and in combination with hbb to determine the most appropriate strategy for improving pain perception in outpatients.

Eligibility criteria:
inclusion criteria: * female patients older than 18 years who signed informed consent; * patients who need an office hysteroscopy for their diagnosis or treatment. those indications included postmenopausal endometrial thickening (over 4 mm), metrorrhagia, sonographic suspicion of endometrial polyps or myomas, essure device insertion, and endometrial biopsy exclusion criteria: * women with a possible pregnancy, ongoing vaginal bleeding, lower genital tract infection, gestational trophoblastic disease, asthma, hepatitis, renal failure, lactation, previous cervical surgery, or oversensitivity to one of the agents or their elements; * patients suffering from neuropathic pain or other conditions that can impact on the perception of pain; * individuals who use antidepressant, anxiolytics or other drugs/supplements that may have an impact on the perception of pain; * contraindications to the use of ibuprofen and/or hyoscine n-butil bromide .

Keywords: hysteroscopy
single dose ratg for renal allograft rejection

Conditions: Acute (Cellular) Renal Allograft Rejection

Summary: rabbit antithymocyte globulin (ratg) is approved for the treatment of acute rejection following kidney transplantation and is routinely administered as a series of 5-7 consecutive daily doses via central intravenous catheter.single large-doses of ratg have been shown to have equivalent safety and efficacy profile compared to the standard daily protocol when used as an induction agent but there are no reported experiences of its use for rejection treatment. plan to study a single-dose ratg infusion compared to standard ratg administration including correlation to length of hospital stay and hospital costs.

rabbit antithymocyte globulin (ratg) is approved for the treatment of acute rejection following kidney transplantation and is routinely administered as a series of 5-7 consecutive daily doses via central intravenous catheter. this prolonged course is not consistent with the medicare diagnosis-related group (drg) for acute rejection which limits rejection admission to 3 days. the prolonged hospitalization results in increased medical costs and uniform financial loss to the hospital for patients admitted under this drg. in addition there is a patient related toll of the prolonged hospitalization and a potential for additional hospital acquired complications. single large-doses of ratg have been shown to have equivalent safety and efficacy profile compared to the standard daily protocol when used as an induction agent but there are no reported experiences of its use for rejection treatment. the investigators hypothesize that single-dose ratg infusion will be as safe and efficacious as standard ratg administration when used for rejection treatment and would result in significant reduction in the length of hospital stay (los) and hospital costs for rejection treatment.

Eligibility criteria:
inclusion criteria: 1. male or female subjects aged 18 years or older 2. experiencing a biopsy-proven acute rejection episode which: * will require the use of ratg based on severity, or * is exhibiting resistance to corticosteroid treatment, defined as failure of the serum creatinine to decrease after at least 3 days of corticosteroid treatment (≥200 mg/day of methylprednisolone or equivalent) exclusion criteria: 1. patients with known severe allergy to antithymocyte globulin or rabbits 2. rejection episode requiring the use of therapeutic plasma exchange immediately subsequent to ratg administration 3. currently receiving any investigational drug or treatments

Keywords: kidney transplantation acute rejection rabbit antithymocyte globulin
diagnostic three dimensional echocardiography study protocol

Conditions: Aortic Valve Stenosis; Aortic Valve Insufficiency

Summary: the purpose of this study is to perform ground-based research to study what happens to the heart muscle in space. people who have problems with their aortic valve have an increase in the amount of muscle in the left ventricle of the heart. after valve surgery, the amount of muscle should decrease and return to normal. astronauts lose heart muscle mass during space flight. our study will look at these changes in your heart, which we believe are similar to what happens during long term space travel. this study will look at the accuracy of three dimensional ultrasound imaging (echo) in monitoring the changes in heart size and function following aortic valve replacement. we are studying ways to prevent health-related problems that men and women will face on long-duration space missions. the hypothesis is that serial two dimensional and three dimensional echo will show accurate changes in the left ventricle mass and volume following aortic valve replacement for aortic stenosis or regurgitation

diagnostic three dimensional echocardiography study protocol a. aims the overall purpose of this study is to perform ground-based research, development, and validation aimed at optimizing diagnostic ultrasound in manned spaceflight, with the following unifying hypothesis: serial 3d ultrasound examinations will enhance diagnostic capabilities in manned spaceflight. specific aims: 1. to optimize acquisition methods for 3d sonography using reconstruction and real-time techniques 2. to determine the utility of serial 3d ultrasound examinations in identifying renal calculi and their complications including the development and resolution of hydronephrosis and calyceal dilatation. 3. to determine the utility of serial 2d and 3d ultrasound examinations in demonstrating cardiac remodeling (changes in cardiac dimensions, volume, mass and function) and defining its determinants after left ventricular unloading following aortic valve replacement for aortic stenosis or regurgitation. 4. to determine whether changes in plasma bnp levels accurately reflect changes in lv mass and volume. hypotheses: 1. serial 3d ultrasound examinations will allow accurate diagnosis of nephrolithiasis and tracking of complications including hydronephrosis and calyceal dilatation 2. serial 2d and 3d ultrasound will allow accurate tracking of changes in lv mass and volume following aortic valve replacement (avr) for aortic stenosis or regurgitation. 3. changes in plasma bnp levels will fall in proportion to the decrease in lv mass and volume.

Eligibility criteria:
inclusion criteria: * scheduled for surgery for aortic stenosis or aortic regurgitation exclusion criteria: * previous open heart surgery

Keywords: aortic valve stenosis aortic valve insufficiency two dimensional echocardiography three dimensional echocardiography
development of an ai solution to evaluate clinical activity of tao using periocular images taken by smartphones in patients with thyroid dysfunction

Conditions: Thyroid Eye Disease

Summary: this study was conducted to develop an ai solution to evaluate clinical activity score (cas) of thyroid associated orbitopathy (tao) using periocular selfie images taken by smartphones in patients with thyroid dysfunction. an ai solution to evaluate cas in tao was developed in previous retrospective study using periorbital digital images taken by dslr camera in the studio. this ai solution will be adjusted to show its best performance with periocular selfie images taken by smartphones.


Eligibility criteria:
inclusion criteria: * patients with thyroid eye disease exclusion criteria: * patients who have prior facial anomaly or surgery * patients who cannot use smartphone camera app

Keywords: thyroid eye disease artificial intelligence machine learning smartphone
comparison of effectiveness of amniotic membrane and duoderm dressings in pediatric burns

Conditions: Burns

Summary: there is a difference in frequency of wound infection, mean pain score, mean of time for skin grafting and hospital stay in pediatric 2nd and 3rd degree burns, between amniotic membrane and duoderm dressings

after informed consent of the patients, patients who will fulfill the inclusion and exclusion criteria will be enrolled in the study from department of pediatric surgery, mayo hospital lahore and will be randomly allocated by lottery method into 2 groups by the doctor. group a and b with 86 patients in each group. group a patients will be undergoing amniotic membrane dressing, while group b patients will undergo colloid gel foam dressing. basic demographic information will be noted. effect modifiers (hemoglobin level, weight and height) will be noted. in group a, the wounds will be washed with normal saline and then covered with amniotic membrane over which a layer of vaseline gauze will be applied and dressing with gauze and the crape bandage will be applied. every 3-4 days these dressings will be changed and assessed for pain, wound infection and wound c/s will be sent. placentas from clean vaginal deliveries and elective c-sections will be taken. blood of mother will be screened. amniotic membrane will be separated from placenta in a clean sterile bowl. bowl will be put in refrigerator at 4 degrees. in group b, wound will be washed with normal saline . the wound site will be covered with colloid gel foam and gauze, and crape bandage will be applied. dressing will be changed after 3-4 days. the outcome (pain score, wound infection,time for skin grafting and hospital stay) will be compared in both groups.

Eligibility criteria:
inclusion criteria: * 10-45 % percent 2nd and 3rd degree fresh burns age less than 12 years patients of both gender exclusion criteria: * patients whose parents are not willing patients whose wound c/s comes positive at the time of admission patients who have associated medical disorder and trauma.

Keywords: pediatric burns, dressings, amniotic membrane, duoderm